- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05850936
Effekt av IOP-senking på progressiv HM (PHM)
Effekt av medisinsk intraokulært trykksenking på progressiv høy nærsynthet
Currently, whether and when intraocular pressure (IOP) lowering medication should be used in progressive high myopia (HM) to control axial elongation is still a dilemma. Randomized trials are required to evaluate whether IOP lowering influences the growth of axial length in progressive HM eyes.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Myopia has emerged as a major health issue in east Asia, especially the sight-threatening complications associated with high myopia (HM). Complication of HM can be associated with significant ocular morbidities including maculopathy, retinal detachment, and glaucoma.
Previous studies have shown that adult patients with HM have sustained growth of the axial length (AL), which is a risk factor for the progression of pathological myopia and thus may further affect the visual function , so how to slow down the sustained growth of the AL in adult patients with HM has become an urgent clinical problem. Previous studies have shown that IOP-lowering treatment is a protective factor for the growth of the AL in HM , and the results of animal experiments have further shown that medically IOP-lowering treatment can significantly slow down the AL lengthening and refractive changes in the guinea pig model of myopia. On this basis, the investigators proposed in a previous article that medically IOP-lowering treatment may slow down the growth of AL by three pathways related to the sclera and choroid: for the sclera, IOP-lowering treatment may reduce the scleral distending force, slow down the rate of scleral distension, and inhibit the activation of scleral fibroblasts to reduce scleral remodeling; for the choroid, IOP-lowering treatment may increase choroidal blood perfusion and for the choroid, hypotensive treatment can increase choroidal perfusion and thus reduce scleral remodeling due to scleral hypoxia. A previous retrospective study conducted by the investigators also shows that medically IOP-lowering treatment could control the progression of AL in HM, but there is still a lack of evidence from relevant robust randomized controlled clinical trials (RCT).
The investigators propose to conduct a RCT to evaluate whether medically IOP-lowering therapy is effective in controlling the progression of AL in HM. Secondly, this study also aims to provide data to evaluate IOP-lowering treatment effects on the incidence of changes in the visual field (VF), optic nerve head morphology including the retinal nerve fiber layer (RNFL), and retinal ganglion cell-inner plexiform layer (GC-IPL) loss, progression of myopic maculopathy, loss in visual function and change in quality of life. The outcomes of this study may provide a strong basis for treatment recommendations to control the progression of high myopic eyes, and to provide high-quality clinical research evidence for international clinical guidelines on myopia.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510060
- Zhongshan Ophthalmic Center, Sun Yat-sen University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Informed consent given, and consent form signed.
- Age between 18 and 65 years.
- Diagnosed with HM: spherical equivalent ≤ -6.00 diopters or AL ≥ 26.5 mm.
- Progressive HM: progression in AL ≥0.05mm in the past 6 months or ≥0.1mm in the past 12 months.
- IOP ≥ 10 mmHg and ≤ 21mmHg on at least 2 visits, as measured by Goldmann applanation tonometry .
- Best corrected visual acuity (BCVA) ≥ 6/12, and being able to obtain adequate AL examination, fundus photographs, optical coherence tomography (OCT) and complete the VF examination.
Exclusion Criteria:
- Allergic to any kind of IOP-lowering therapy.
- Combination of various serious fundus pathologies, such as proliferative diabetic retinopathy, retinal detachment, central retinal artery occlusion, etc.
- Combination of chronic, recurrent or severe ocular inflammatory lesions, such as chronic or recurrent uveitis.
- Patients with significant corneal or iris lesions, or severe cataract affecting fundus examination, or patients with only one eye.
- Patients who have undergone any surgery or laser treatment affecting eye parameters during the follow-up period (within the last 1 year), such as cataract surgery.
- Patients with other serious systemic diseases, such as hypertension, heart disease, diabetes, rheumatic immune system disease, etc., who cannot tolerate long-term follow-up and eye treatment.
- Pregnant or lactating women, or those who plan to have children during the follow-up period.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Intervention arm
medical reduction of IOP by eyedrops |
IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the choice for treatment. |
|
Ingen inngripen: control arm
follow up without medication |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Annualized change in axial length (AL) from baseline to 12 months
Tidsramme: 12 months
|
The cumulative change in AL from baseline to 12 months. |
12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Annualized change in axial length (AL) from baseline to 24 months
Tidsramme: 24 months
|
The cumulative change in AL from baseline to 24 months divided by 2 years. |
24 months
|
|
Annualized change in axial length (AL) from baseline to 36 months
Tidsramme: 36 months
|
The cumulative change in AL from baseline to 36 months divided by 3 years. |
36 months
|
|
Change in spherical equivalent (SE) from baseline
Tidsramme: 12, 24, and 36 months
|
Change in spherical equivalent refraction (SE) from baseline. |
12, 24, and 36 months
|
|
Change in intraocular pressure (IOP) from baseline
Tidsramme: 12, 24, and 36 months
|
Change in intraocular pressure (IOP) from baseline |
12, 24, and 36 months
|
|
Change in choroidal thickness (ChT) from baseline
Tidsramme: 12, 24, and 36 months
|
Change in subfoveal choroidal thickness (ChT) measured by OCT from baseline. |
12, 24, and 36 months
|
|
Change in visual field (VF) parameters and incidence/progression of VF defects
Tidsramme: 12, 24, and 36 months
|
Change in Humphrey 24-2 mean deviation (MD) and pattern standard deviation (PSD) from baseline, and the incidence and progression of visual field defects |
12, 24, and 36 months
|
|
Change in retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) thickness
Tidsramme: 12, 24, and 36 months
|
Change in peripapillary RNFL and macular GCIPL thickness measured by OCT from baseline |
12, 24, and 36 months
|
|
Change in retinal and choroidal vascular parameters measured by OCTA
Tidsramme: 12, 24, and 36 months
|
Change in vessel density of the superficial capillary plexus (SCP) and deep capillary plexus (DCP), and choriocapillaris (CC) flow metrics from baseline |
12, 24, and 36 months
|
|
Incidence of optic nerve head morphological changes
Tidsramme: 12, 24, and 36 months
|
Incidence of morphological changes based on stereoscopic fundus photography, including increased cup-to-disc ratio, neuroretinal rim notching, wedge-shaped RNFL defects, or disc hemorrhage. |
12, 24, and 36 months
|
|
Incidence and progression of myopic maculopathy (MMD)
Tidsramme: 12, 24, and 36 months
|
The incidence and progression rate of myopic maculopathy classified by the international photographic classification system. |
12, 24, and 36 months
|
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Tidsramme: 1 month, 3 month, 6 month, 12 month, 24 month, 36 month
|
The incidence, severity, and relationship to study medication of all adverse events (AEs) and serious adverse events (SAEs) |
1 month, 3 month, 6 month, 12 month, 24 month, 36 month
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Xiulan Zhang, MD, PhD, Sun Yat-sen University
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Leske MC, Heijl A, Hyman L, Bengtsson B. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999 Nov;106(11):2144-53. doi: 10.1016/s0161-6420(99)90497-9.
- Leske MC, Hyman L, Hussein M, Heijl A, Bengtsson B. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1999 May;127(5):625-6. No abstract available.
- Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara-Blanco A, Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, McNaught AI, Negi A, Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald RP, Xing W, Zeyen TG. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015 Apr 4;385(9975):1295-304. doi: 10.1016/S0140-6736(14)62111-5. Epub 2014 Dec 19.
- Jiang J, Lin T, Lin F, Kong K, Wang P, Song Y, Zhou F, Wang Z, Jin L, Liu Y, Gao X, Chen J, Chen M, Lam DSC, Jonas JB, Chen S, Zhang X; Glaucoma Suspects with High Myopia Study Group. Effect of intraocular pressure reduction on progressive high myopia (PHM study): study protocol of a randomised controlled trial. BMJ Open. 2024 Jun 5;14(6):e084068. doi: 10.1136/bmjopen-2024-084068.
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- 2023KYPJ110
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .